Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.

You may also be interested in...



Dificid Launch On Path To Success

Optimer Pharmaceuticals’ antibiotic Dificid is on track to exceed one-year targets agreed upon with co-promotion partner Cubist.

Optimer Fires Execs For Questionable Financial Practices

A year after FDA approval of its antibiotic Dificid, the Optimer board has ousted its chairman and at least two other top executives.

Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators

EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel